Utilizing the apo E and LDL receptor knockout mouse models of atherosclerosis, this project proposes to identify new genes and pathways relevant to atherosclerosis susceptibility by applying the powerful techniques of mouse genetics and the emerging tools of the Genome Project. In addition, the experimental approach will heavily emphasize physiological studies of atherosclerosis related phenotypes both as an aid to gene identification and to better stand the function of apo E knockout, and a resistant strain, FVB/N apo E knockout, has revealed 3 atherosclerosis susceptibility loci not associated with lipoprotein phenotype.
The specific aims are: 1) To identify the physiological and genetic basis of the knockout, strains. This will entail studies comparing parental strains for lesion progression, tissue contributions, macrophage metabolism, and gene expression. To identify the gene, secondary congenics will be made and the phenotype reconstructed. Secondary congenic will then be backcrossed and recombinants sought to narrow the genetic intervals. Ultimately, the response gene(s) will be identified through gene expression studies, sequencing, and creating transgenic or knockout mouse models. (2) To perform additional crosses between atherosclerosis susceptible and resistant apo E knockout and LDL receptor knockout mouse strains to reveal new genes that control atherosclerosis susceptibility. The first experiment will attempt to identify genes involved in lesion progression by crossing C57/Bl/6J apo E knockout and FVB/N apo E knockout mice with scoring of lesions in F2 mice on a chow diet at 40 weeks of age for lesion size, acellular lipid core size, collagen and smooth muscle cell content, and calcification. A second C57/Bl/6J apo E knockout mice) and FVB/N apo E knockout mice to identify a gender influenced atherosclerosis susceptibility gene. Finally, to create a FVB/N LDL receptor knockout and cross it with the C57Bl/6J LDL receptor knockout strain to identify genes that influence atherosclerosis susceptibility on the LDL receptor knockout but not the apo E knockout background. This project should identify new genes and pathways involved in atherosclerosis susceptibility.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL054591-07
Application #
6479998
Study Section
Project Start
2001-07-01
Project End
2002-06-30
Budget Start
Budget End
Support Year
7
Fiscal Year
2001
Total Cost
$268,239
Indirect Cost
Name
Rockefeller University
Department
Type
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Fredman, Gabrielle; Kamaly, Nazila; Spolitu, Stefano et al. (2015) Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med 7:275ra20
Libby, Peter; Tabas, Ira; Fredman, Gabrielle et al. (2014) Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 114:1867-79
Subramanian, Manikandan; Tabas, Ira (2014) Dendritic cells in atherosclerosis. Semin Immunopathol 36:93-102
Subramanian, Manikandan; Hayes, Crystal D; Thome, Joseph J et al. (2014) An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo. J Clin Invest 124:1296-308
Nagareddy, Prabhakara R; Murphy, Andrew J; Stirzaker, Roslynn A et al. (2013) Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 17:695-708
Subramanian, Manikandan; Thorp, Edward; Hansson, Goran K et al. (2013) Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J Clin Invest 123:179-88
Gautier, Emmanuel L; Westerterp, Marit; Bhagwat, Neha et al. (2013) HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med 210:339-53
Rodríguez, José M; Wolfrum, Susanne; Robblee, Megan et al. (2013) Altered expression of Raet1e, a major histocompatibility complex class 1-like molecule, underlies the atherosclerosis modifier locus Ath11 10b. Circ Res 113:1054-64
Tabas, Ira; Glass, Christopher K (2013) Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339:166-72
Rong, James X; Blachford, Courtney; Feig, Jonathan E et al. (2013) ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity. Arterioscler Thromb Vasc Biol 33:4-12

Showing the most recent 10 out of 124 publications